ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

ARGENX SE

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026

$825.61+6.47 (+0.79%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 42.2
Dividend yield: –

ARGENX SE income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	–	–	36	10	497	41	78	21	–	–	–
Cost of Revenue	451	227	118	29	–	–	–	–	–	–	–
Gross Profit	–	–	-82	-19	–	–	–	–	–	–	–
Research & Development	1,364	983	859	663	581	371	221	84	–	–	–
Selling, General & Admin	1,367	1,055	712	472	–	–	–	–	–	–	–
Selling & Marketing	395	307	202	116	60	–	–	–	–	–	–
Operating Expenses	3,194	2,274	1,694	1,166	888	543	293	–	–	–	–
Operating Income	1,054	-22	-425	-720	-349	-478	-199	-82	–	–	–
Interest Expense	4.08	2.46	0.91	3.91	4.58	7.96	–	–	–	–	–
Interest & Investment Income	163	158	107	28	3.63	6.46	16	–	–	–	–
Pretax Income	1,279	85	-304	-729	-400	-605	-176	–	–	–	–
Income Tax Expense	-13	-748	-9.44	-20	8.52	3.10	5.29	–	–	–	–
Net Income incl. Noncontrolling Interests	1,292	833	-295	-710	-408	-608	-181	-67	–	–	–
Net Income	1,292	833	-295	-710	-408	-608	–	–	–	–	–
Net Income to Common	1,292	833	-295	-710	-408	-608	–	–	–	–	–
EPS (Basic)(per share)	21.08	13.92	-5.16	-13.05	-7.99	-13.40	-4.69	–	–	–	–
EPS (Diluted)(per share)	19.57	12.78	-5.16	-13.05	-7.99	-13.40	-4.69	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	61	60	57	54	51	45	39	33	25	19	16
Shares Outstanding (Diluted, Weighted)(shares)	66	65	57	54	51	45	39	33	25	19	16

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 5.12
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 227.6%

Valuation

P/E ratio: 42.2
Price to sales: –
Price to book: –
Dividend yield: –